度普利尤单抗延长给药间隔治疗慢性鼻窦炎伴鼻息肉的Meta分析
结果显示Q4W在SNOT-22、鼻塞、嗅觉、鼻息肉评分及Lund-Mackay评分上无显著变化,嗜酸性粒细胞显著下降,真实世界研究提示部分患者可进一步延长至Q6W-Q12W。
要点
- 度普利尤单抗延长至Q4W后,SNOT-22、鼻塞、嗅觉、鼻息肉评分及Lund-Mackay评分无显著变化。
- 真实世界研究显示部分患者可进一步延长至Q6W-Q12W。
核心结论
- 度普利尤单抗在标准剂量治疗6至12个月后延长至Q4W可维持临床稳定性。
- 部分患者可进一步延长给药间隔至Q6W-Q12W。
- 仍需对照试验明确最佳减量策略及成功延长间隔的预测因素。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Scopus、Cochrane Library和Web of Science,最终检索2025年9月。
- 纳入标准为从度普利尤单抗300 mg Q2W转换为延长间隔(≥Q4W)的成人CRSwNP患者。
- 两名评审员独立筛选、提取数据并使用RoB2和NIH工具评估偏倚风险。
- 采用随机效应Meta分析合成鼻窦、影像学及生物标志物结局。
主要发现
- 汇总均数差(Q4W vs Q2W)显示SNOT-22变化-0.56,无统计学意义。
- 鼻塞变化-0.73,嗅觉变化+0.23,鼻息肉评分变化-0.29,Lund-Mackay评分变化-1.25,均无统计学意义。
- 亚组分析显示12个月与6个月诱导方案后Q4W给药的临床结局差异无统计学意义。
- 真实世界研究显示部分患者可进一步延长至Q6W-Q12W。
关键数值与推荐
- 延长间隔定义为≥Q4W,标准方案为度普利尤单抗300 mg Q2W。
- 定量合成纳入9项研究,共1075例患者。
- SNOT-22均数差-0.56,鼻塞-0.73,嗅觉+0.23,鼻息肉评分-0.29,Lund-Mackay评分-1.25。
临床怎么用
- 成人CRSwNP患者在度普利尤单抗标准Q2W治疗6至12个月后可考虑延长至Q4W以维持疾病控制。
- 部分选择患者可进一步延长至Q6W-Q12W,但需个体化评估。
- 延长间隔决策应结合临床、影像学及生物标志物综合判断。
局限性
- 仅9项研究贡献定量合成,样本量有限。
- 真实世界研究提示的进一步延长间隔(Q6W-Q12W)证据来自特定患者。
- 需进一步对照试验明确最佳减量策略及预测因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether extending the dupilumab dosing interval beyond the standard every-two-weeks (Q2W) regimen maintains clinical, radiologic, and biomarker control in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). DATA SOURCES: PubMed, Scopus, Cochrane Library, and Web of Science were systematically searched using predefined terms related to CRSwNP and dupilumab, with the final search in September 2025. Reference lists of included studies were also screened. REVIEW METHODS: Eligible studies enrolled adults with CRSwNP who transitioned from dupilumab 300 mg Q2W to extended intervals (≥Q4W). Two reviewers independently screened, extracted data, and assessed risk of bias using RoB2 and NIH tools. Random-effects meta-analyses synthesized sinonasal, radiologic, and biomarker outcomes. Subgroup analysis also compared switching after 6 versus 12 months of standard-dosing induction period. RESULTS: Nineteen studies met the inclusion criteria, and nine contributed to quantitative synthesis. Across 1075 patients, extended interval dosing preserved disease control. Pooled mean differences (Q4W vs Q2W) showed non-significant changes in 22-item Sinonasal Outcome Test (SNOT-22) (-0.56), nasal congestion (-0.73), olfaction (+0.23), nasal polyp score (-0.29), and Lund-Mackay score (-1.25). Eosinophils decreased significantly (-0.13 × 109/L; P = .047). Subgroup analysis revealed a non-significant difference in clinical outcomes of Q4W dosing when comparing the 12- and 6-month induction protocols. Real-world studies showed the feasibility of further extension (Q6W-Q12W) in selected patients. CONCLUSION: Dupilumab interval extension to Q4W maintains clinical stability after 6 to 12 months of standard dosing, with potential for longer intervals in selected patients. Further controlled trials are required to define optimal tapering strategies and identify predictors of successful dose spacing.
引用
- Alqutub A, Herzallah AI, Alqutub S, et al. Dupilumab Extended Interval Dosing in Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review and Meta-analysis. Otolaryngol Head Neck Surg. 2026. PMID: 42290623. doi:10.1002/ohn.70295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。